



Approved for use through 03/31/2007. CMB 0651-2031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/560,385-Conf. #3846
		Filing Date	January 12, 2007
		First Named Inventor	Michael G. Orchard
		Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet	1	of	3
		Attorney Docket Number	A0345.0021

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA	EP-0 536 402	04-14-1993	Nippon Shinyaku Company		✓
	BB	EP 0 698 012 (WO-94/26714)	11-24-1994	G.D. Searle & Co et al.		✓

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
CA		GIULIO ALESSANDRI, ET AL., "Angiogenic and Angiostatic Microenvironment in Tumors," <i>Anct Onco.</i> (1997), 36(4), pp. 383-387		
CB		ANTHONY LUCCI, ET AL., "Glucosylceramide: a Marker for Multiple-Drug Resistant Cancers," <i>Anticancer Res.</i> (1998), 18(1B), pp. 475-480		
CC		PETER DE MAN, ET AL., "Bacterial adherence as a virulence factor in urinary tract infection," <i>APMIS</i> (1990), 98(12), pp. 1053-1060		
CD		KM NICHOLSON, ET AL., "Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase," <i>Br. J. Cancer</i> (1999), 81(3), pp. 423-430		
CE		GUNNAR C. HANSSON, ET AL., "A novel approach to the study of glycolipid receptors for viruses," <i>FEBS Lett.</i> (1984), 170(1), pp. 15-18		
CF		VICTOR JIMENEZ-LUCHO, ET AL., "Cryptococcus neoformans, Candida albicans, and Other Fungi Bind Specifically to the Glycosphingolipid Lactosylceramide (Galβ1-4Glcβ1-1Cer), a Possible Adhesion Receptor for Yeasts," <i>Infect. Immun.</i> (1990), 58(7), pp. 2085-2090		
CG		YAAKOV LAVIE, ET AL., "Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells," <i>J. Biol. Chem.</i> (1997), 272(3), pp. 1682-1687		
CH		YONG-YU LIU, ET AL., "Uncoupling Ceramide Glycosylation of Transfection of Glucosylceramide Synthase Antisense Reverses Adriamycin Resistance," <i>J. Biol. Chem.</i> (2000), 275(10), pp. 7138-7143		
CI		RUIXIANG LI, ET AL., "Cellular Gangliosides Promote Growth Factor-induced Proliferation of Fibroblasts," <i>J. Biol. Chem.</i> (2000), 275(44), pp. 34213-34223		
CJ		IVAN Z. ZADOR, ET AL., "A Role for Glycosphingolipid Accumulation in the Renal Hypertrophy of Streptozotocin-induced Diabetes Mellitus," <i>Clin. Invest.</i> (1993), 91(3), pp. 797-903		
CK		AKIRA ABE, ET AL., "Reduction of globotriaosylceramide in Fabry disease mice by substrate		
Examiner Signature	/John Mabry/ (04/02/2010)		Date Considered	

PTO/SB/08A/B (09-06)  
 Approved for use through 03/31/2007. OMB 0651-0031  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/560,385-Conf. #3846
				Filing Date	January 12, 2007
				First Named Inventor	Michael G. Orchard
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	A0345.0021

	deprivation," J. Clin. Invest. (2000), 105(11), pp. 1563-1571	
CL	ROBERT MCKALLIP, ET AL., "Tumor Gangliosides Inhibit the Tumor-Specific Immune Response," J. Immunol. (1999), 163(7), pp. 3718-3726	
CM	MAJLIS SVENSSON, ET AL., "Carbohydrate Receptor Depletion as an Antimicrobial Strategy for Prevention of Urinary Tract Infection," J. Infect. Dis. (2001), suppl. 70-73, p. 183	
CN	SUBROTO CHATTERJEE, ET AL., "Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease," J. Lipid. Res. (1996), 37(6), pp. 1334-1344	
CO	TIMOTHY COX, ET AL., "Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis," Lancet (2000), 355(9214), pp. 1481-1485	
CP	N.V. PROKAZOVA, ET AL., "Gangliosides and Atherosclerosis," Lipids (1994), 29(1), pp. 1-5	
CQ	KAZUKO HANDA, ET AL., "Analysis of Glycolipid-Dependent Cell Adhesion Based on Carbohydrate-Carbohydrate Interaction," Methods Enzymol. (2000), 312, pp. 447-458	
CR	CLIFFORD A. LINGWOOD, ET AL., "Analysis of Interactions between Glycosphingolipids and Microbial Toxins," Methods Enzymol. (2000), 312, pp. 459-473	
CS	ABDERRAHIM MERZAK, ET AL., "Gangliosides Modulate Proliferation, Migration, and Invasiveness of Human Brain Tumor Cells In Vitro," Mol. Chem. Neuropathol. (1995), 24(2-3), pp. 121-135	
CT	KAI SIMONS ET AL., "Functional rafts in cell membranes," Nature (1997), 387(6633), pp. 569-572	
CU	PRAVEEN TYLE, "Ionophoretic Devices for Drug Delivery," Pharmaceutical Research (1986), 3(6), p. 318	
CV	LINDA A. GOODMAN, ET AL., "Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in $\alpha$ -mannosidosis," Proc. Natl. Acad. Sci. USA (1991), 88(24), pp. 11330-11334	
CW	CHIL-SHIARING CHEN, ET AL., "Abnormal transport along the lysosomal pathway in Mucopolidosis, type IV disease," Proc. Natl. Acad. Sci. USA (1998), 95(11), pp. 6373-6378	
CX	MYLVAGANAM JEYAKUMAR, ET AL., "Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin," Proc. Natl. Acad. Sci. USA (1999), 96(11), pp. 6388-6393	
CY	Protective Groups in Organic Chemistry, T.W. Greene and P.G.M. Wuts, (Wiley-Interscience, New York, 2nd edition) (1991)	
CZ	FRANCES M. PLATT, ET AL., "Prevention of Lysosomal Storage in Tay-Sachs Mice Treated with N-Butyldeoxynojirimycin," Science (1997), 276(5311), pp. 428-431	
CA1	MILTON ALTER, "GM <sub>1</sub> Ganglioside for Acute Ischemic Stroke," Alter, Ann. NY Acad. Sci. (1998), 845, pp. 391-401	
CB1	LIN-PING CHOO-SMITH ET AL., "Acceleration of Amyloid Fibril Formation by Specific Binding of A $\beta$ -(1-40) Peptide to Ganglioside-containing Membrane Vesicles," Biol. Chem. (1997), 272, pp. 22987-22990	
CC1	FOWLER, P.A. ET AL., "Synthesis and activity towards yeast $\alpha$ -glucosidase of 1,5-dideoxy-1,5-imino-L-iditol (1-deoxy-L-idonojirimycin), Carbohydr. Res. (1993), 246, pp. 377-381	
CD1	FRED H. GEISLER, "Clinical Trials of Pharmacotherapy for Spinal Cord Injury," NY Acad. Sci. (1998), 845, pp. 374-381	
CE1	MEMON, R.A. ET AL., "Regulation of Glycosphingolipid Metabolism in Liver during the Acute Phase Response," J. Biol. Chem. (1999), 274(28), pp. 19707-19713	
CF1	MEMON, R.A., ET AL., "Regulation of sphingolipid and glycosphingolipid metabolism in	

Examiner Signature	/John Mabry/ (04/02/2010)	Date Considered	
--------------------	---------------------------	-----------------	--

PTO/SB/06A/B (06-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/560,385-Conf. #3846
				Filing Date	January 12, 2007
				First Named Inventor	Michael G. Orchard
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	A0345.0021

		extrahepatic tissues by endotoxin," J. Lipid. Res. (2001), 42(3), pp. 452-459	
CG1	OVERKLEEF, H.S. ET AL., "Generation of Specific Deoxynojirimycin-type Inhibitors of the Non-lysosomal Glucosylceramidase," J. Biol. Chem. (1998), 273, pp. 26522-26527		
CH1	FRANCES M. PLATT ET AL., "N-Butyldeoxygalactonojirimycin Inhibits Glycolipid Biosynthesis but Does Not Affect N-Linked Oligosaccharide Processing," J. Biol. Chem. (1994), 269, pp. 27108-27114		
CI1	RAO, V.S. ET AL., "Regioselective eliminations in reactions of carbohydrate derivatives with superoxide, or with borohydride in 2-propanol," Can. J. Chem. (1981), 59(2), pp. 333-338		
CJ1	RYAN, J.L. ET AL., "Changes in Membrane Gangliosides: Differentiation of Human and Murine Monocytic Cells," Yale J. Biol. Med. (1985), 58(2), pp. 125-131		
CK1	J.S. SCHNEIDER, "GM1 Ganglioside in the Treatment of Parkinson's Disease," Anatomy and Cell Biology, (1990), 845, pp. 363-373		
CL1	KATSUHIKO YANAGISAWA ET AL., "GM1 ganglioside-bound amyloid $\beta$ -protein (A $\beta$ ): A possible form of preamyloid in Alzheimer's disease," Nat. Med. (1995), 1, pp. 1062-1066		
CM1	HERBERT C. YOHE, ET AL., "Ganglioside alterations in stimulated murine macrophages," Biochim. Biophys. Acta (1985), 818(1), pp. 81-86		
CN1	HERBERT C. YOHE, ET AL., "Ganglioside expression in Macrophages from Endotoxin Responder and Non-Responder Mice," Immunol. (1986), 137(12), pp. 3921-3927		
CO1	HERBERT C. YOHE ET AL., "The Presence of Sialidase-Sensitive Sialosylganglioside (G <sub>M1b</sub> ) in Stimulated Murine Macrophages," Immunol. (1991), 146(6), pp. 1900-1908		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/John Mabry/ (04/02/2010)	Date Considered	
-----------------------	---------------------------	--------------------	--

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

DOCSN: 271197-01